Sanofi S.A. published its third-quarter earnings report on Friday, saying that its IFRS net sales declined by 4.1% on an annual basis to land at €11.96 billion. The company's IFRS net income amounted to €2.53 billion, up 21.6% compared to the same period of 2022, while its IFRS earnings per share jumped 21.1% in the third trimester to reach €2.01.
The French pharmaceutical giant's business EPS fell by 11.5% to €2.55 and business net income decreased by 11.4% to €3.2 billion. Business operating income was down 10.4% to €4.03 billion.
"As we enter a compelling next chapter of our company's Play to Win strategy, we remain confident in the outlook for the last quarter and consequently keep our full-year earnings guidance unchanged," Sanofi's CEO Paul Hudson said.
